A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
We are doing this research study because we are trying to learn more about a drug called Denosumab in children with glucocorticoid-induced osteoporosis.
- IRB Number: 1809456517
- Research Study Identifier: TX10326
- Principal Investigator: Erik Imel, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required